Sklar Personal Care’s drug facility failed CGMP (current good manufacturing practice), including untested raw materials and inadequate cleaning, process validation, and quality oversight.
What happened
FDA inspected the drug manufacturing facility in Statesville, North Carolina, from May 19 to May 23, 2025 and on June 9, 2025. It found no identity testing for incoming raw materials, no methanol testing for one raw material, no cleaning validation, no process validation for OTC (over-the-counter) products, inadequate water-system monitoring, and quality-unit gaps. FDA reviewed the firm’s June 16, 2025 response and found it inadequate.
What FDA found
The firm did not test each incoming raw material for identity before making OTC drugs and did not test one raw material for methanol.
21 CFR 211.84(d)(1)The firm lacked cleaning validation for shared equipment, so it did not show that cleaning removes residues and prevents carryover between products.
21 CFR 211.67(b)The firm did not perform process validation for all OTC drug products before commercial distribution.
21 CFR 211.100(a)The firm’s water system used in drug products and equipment cleaning was not adequately tested, monitored, or sanitized.
21 CFR 211.100(a)The quality unit did not perform annual product reviews since 2022 and did not follow its raw-material sampling procedure, risking contamination and mix-ups.
21 CFR 211.22(d)
What FDA wants
FDA asks the firm to correct the violations promptly and respond in writing within 15 working days with remediation plans and supporting data for the material system, cleaning, process validation/water monitoring, and quality unit. If corrective actions cannot be completed, the firm must give reasons and a schedule; FDA also strongly recommends a qualified CGMP consultant.
Who should pay attention
- brands that buy or distribute OTC drug products made at this facility
- companies that accept supplier certificates of analysis instead of raw-material identity testing
- quality teams managing shared equipment cleaning and water systems
This is a summary. Read the original letter on fda.gov.